Global Vitiligo Treatment Market Share, Size, Growth, Forecast: By Treatment Type: Medications, Therapy, Surgery, Others; By Indication Type: Nonsegmental Vitiligo, Segmental Vitiligo, Others; By End User: Hospitals, Aesthetic Clinics, Others; By Route of Administration: Oral, Parenteral, Others; Regional Analysis; Supplier Landscape; 2023-2031

Global Vitiligo Treatment Market Outlook

The global vitiligo treatment market size was valued at USD 428.2 million in 2022 and is projected to grow at a CAGR of 4.30% during the forecast period of 2023-2031 to reach a value of USD 625.4 million by 2031. The market growth can be attributed to the increasing prevalence of vitiligo and the rising demand for effective treatment options.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Vitiligo Treatment Market: Causes, Symptoms, Diagnosis, Treatment and Segmentation

Vitiligo is a skin disorder affecting the original colour of the skin and causing discolouration or fading of the skin colour. Vitiligo is characterised by the formation of macules, patches that are less than or more than 5mm in size.

Vitiligo is mainly caused by the deficiency of melanocytes due to the self-attack by the immune system on its melanocytes. The less production of melanocytes leads to the lower production of the pigment melanin, which is responsible for giving skin colour.

With time, the progression of vitiligo increases, starting from small patches on fewer body parts to larger patches or other parts of the body. Vitiligo generally starts from the hands, legs, palms, feet, and face, but eventually may spread to mucous membranes, eyes and inner ears.

Based on the concentration and affected area, vitiligo is of several types including generalised, segmental, mucosal, focal, trichome, and universal. Vitiligo affects nearly 1% of the population or more across the world and is prevalent equally in people of all genders and races.

Vitiligo is expected to be caused by certain genetic and neurogenic factors, that are toxic to melanocytes and thus can lead to vitiligo. Vitiligo is generally diagnosed with the help of white patches that are visible on the skin. A test based on ultraviolet light is also used to examine and differentiate normal skin from the other affected parts.

Vitiligo is treated using a combination of several therapies that aim at restoring the original skin colour or eliminating the remaining colour to maintain the uniformity of skin colour.

The vitiligo treatment market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Treatment Type

• Medications
  • Calcineurin Inhibitor
  • Corticosteroids
  • Psoralens
• Therapy
  • Depigmentation
  • Light Therapy
• Surgery
  • Skin Grafting
  • Blister Grafting
  • Micro Pigmentation
• Others

Market Breakup by Indication Type

• Nonsegmental Vitiligo

• Segmental Vitiligo

• Others

Market Breakup by End User

• Hospitals

• Aesthetic Clinics

• Others

Market Breakup by Route of Administration

• Oral

• Parenteral

• Topical

• Others

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Scenario

The vitiligo treatment market is primarily driven by the increasing patient pool and rising disease burden. According to the American Academy of Dermatology, nearly one in four Americans suffer from vitiligo, this has stimulated the demand for advanced and effective therapeutic options that are expected to increase market growth. Further, raising awareness among the general population has also led to market growth in developed and developing nations.

With the increasing demand, the key players and major pharmaceutical companies have shifted their focus toward the development of novel therapeutic agents. The growing research and developmental activities and the increasing investments in this sector have also propelled the market growth during the forecast period. For example, Incyte, a key market player is conducting clinical trials for testing the safety and efficacy of ruxolitinib cream for the management of vitiligo.

The vitiligo treatment market revenue growth is driven by technological advancements, and increasing adoption of advanced therapeutics by hospitals, surgical centres, and ambulatory care centres are expected to boost the market growth. Additionally, the rising demand for precision medicine and higher adoption of point-of-care diagnostics and home care settings are expected to augment the market revenue growth during the forecast period.

North America and Asia Pacific to Hold a Significant Share

North America is anticipated to hold the largest share of the vitiligo treatment market owing to the rising disease prevalence, the discovery of advanced diagnostics and therapeutics, and the significant presence of many key players in that region.

The Asia Pacific is expected to witness the fastest growth during the forecast period due to increasing awareness, emerging treatment options, growing research and development activities and favouring government initiatives in the developing nations.

Therapeutic Landscape

There is no approved treatment regimen for the management of vitiligo, and tremendous research and developmental activities are being conducted for the discovery of novel therapeutic agents for better therapeutic efficacy. The treatment involves different medications, several therapies, and various surgical procedures.

Medications and Other Therapies

The type of treatment depends on the age of the patient, the affected area, and the speed of the disease progression. The treatments are based on repigmentation and depigmentation. The medications used are topical corticosteroids and topical calcineurin inhibitors such as pimecrolimus and tacrolimus. These drugs have exhibited beneficial effects in the treatment of the affected skin in the early stages of vitiligo.

Several therapies, such as light therapy have been effective in lowering or stopping the disease progression. The combination of light therapy with other medications has been found effective in vitiligo treatment. Corticosteroids or psoralen are combined with light therapy to return the original skin colour and thus help in the treatment of vitiligo.

Surgical Therapeutic Interventions

Surgical interventions are used for the treatment in case of medications or therapy failure. Skin grafting, blister grafting, and cellular suspension transplant are the commonly used surgeries utilised for restoring the lost colour. 

In skin grafting, the patches of healthy skin colour are grafted to the affected parts to manage the vitiligo progression. Blister grafting is another surgical procedure to create blisters on the pigmented skin through suction. Cellular suspension transplant is a repigmentation procedure to transplant chemically treated cells onto the affected area.

Clinical Trials Landscape of the Vitiligo Treatment Market

With extensive research and development, scientists are effortlessly working on developing novel therapeutic agents that could help in the treatment of vitiligo. Many drugs are being discovered and under different phases of clinical trials for assessing their safety, efficacy, tolerability, and pharmacokinetics.

Emerging Clinical Trials: JAK Inhibitors Have Shown Promising Benefits

Novel therapeutic agents acting against Janus-activated kinases (JAKs) have been proven for the treatment of vitiligo. Many drugs possessing the JAK inhibition mechanism are under clinical trials and are expected to provide therapeutic efficacy in the management of vitiligo.

Baricitinib, a novel JAK1 and JAK2 inhibitor, is under Phase II clinical trials and has shown promising results in the vitiligo treatment in combination with phototherapy. Ifidancitinib, another investigational drug, is tested and possesses JAK1 and JAK3 inhibition properties. Combination therapy of brepocitinib and ritlecitinib is being evaluated in clinical testing and is a JAK3 and tyrosine kinase inhibitor.

Incyte Corporation, a key market player, has discovered a novel therapeutic agent, auremolimab, an anti-monoclonal antibody and is expected to enter clinical development by 2023. This drug acts against the memory T cells that have shown efficacy in the vitiligo treatment.

The United States Food and Drug Administration has recently approved a novel medication, Opezelura cream for the treatment of non-segmental vitiligo. This topical agent has become the first approved treatment for repigmentation in patients and possesses JAK inhibition activity.

Avita Medical, a major company, is conducting clinical trials for the RECELL system, which has demonstrated positive clinical trial results for the treatment of stable vitiligo.

All the discovered treatment approaches are based on the aim of repigmentation and subsequently will help in treating vitiligo. Several ongoing clinical trials are emerging as key trends which are likely to bolster the growth of the market.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the vitiligo treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Dermavant Sciences, Inc. (Roivant Sciences Ltd.)

• Incyte

• Aclaris Therapeutics, Inc.

• Dr Reddy’s Laboratories Ltd.

• GSK plc

• Bristol-Myers Squibb Company

• Clinuvel Pharmaceuticals Ltd

• Applied Biological Laboratories

• Boston Pharmaceuticals

• F. Hoffmann-La Roche Ltd

• Pfizer Inc.

Key Highlights of the Report

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.